circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/beta-catenin pathway
Yaming Li,Zekun Wang,Peng Su,Yiran Liang,Zheng Li,Hanwen Zhang,Xiaojin Song,Dianwen Han,Xiaolong Wang,Ying Liu,Jingwen Yang,Bing Chen,Lijuan Wang,Wenjing Zhao,Qifeng Yang
DOI: https://doi.org/10.1016/j.ymthe.2021.08.026
IF: 12.91
2022-01-01
Molecular Therapy
Abstract:The protein-coding ability of circRNAs has recently been a hot topic, but the expression and roles of protein-coding circRNAs in triple-negative breast cancer (TNBC) remain uncertain. By intersecting circRNA sequencing data from clinical samples and cell lines, we identified a circRNA termed circ-EIF6, which predicted a poorer prognosis and correlated with clinicopathological characteristics in a cohort of TNBC patients. Functionally, we showed that circ-EIF6 promoted the proliferation and metastasis of TNBC cells in vitro and in vivo. Mechanistically, we found that circ-EIF6 contains a 675 nt ORF and that the -150 bp sequence from ATG functioned as an internal ribosome entry site (IRES), which is required for translation initiation in 5′-cap-independent coding RNAs. Circ-EIF6 encodes a novel peptide termed EIF6-224aa, which is responsible for the oncogenic effects of circ-EIF6. The endogenous expression of EIF6-224aa was further examined in TNBC cells and tissues by specific antibody. Moreover, EIF6-224aa directly interacted with MYH9, an oncogene in breast cancer, and decreased MYH9 degradation by inhibiting the ubiquitin-proteasome pathway and subsequently activating the Wnt/beta-catenin pathway. Our study provided novel insights into the roles of protein-coding circRNAs and supported circ-EIF6/EIF6-224aa as a novel promising prognostic and therapeutic target for tailored therapy in TNBC patients.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology